Drug Profile
Research programme: viral encephalitis therapeutics - VGX Pharmaceuticals
Alternative Names: VGX 2000Latest Information Update: 31 Aug 2009
Price :
$50
*
At a glance
- Originator VGX Pharmaceuticals
- Developer Inovio Biomedical Corporation
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Encephalitis virus infections
Most Recent Events
- 29 Mar 2007 Preclinical trials in Encephalitis virus infections in USA (unspecified route)